Global Life Science Ventures

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Action Pharma A/S is a biotechnology company focused on research and development of innovative drug candidates aimed at treating cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company specializes in discovering and developing new treatment concepts, particularly those targeting melanocortin receptors. Its product pipeline includes AP214, a modified peptide analogue for preventing post-surgical kidney injury related to cardiac surgeries, as well as the AP1030 and AP11 series, which are oral anti-diabetic medications designed for patients with type-II diabetes who are overweight or obese. Additionally, Action Pharma is developing AP1189, an oral anti-inflammatory compound for conditions like inflammatory bowel disease and rheumatoid arthritis, and AP405, which targets inflammatory skin diseases such as atopic dermatitis. The company's efforts are geared toward achieving clinical proof of concept for its drug candidates, facilitating partnerships for further development and commercialization.

Coapt Systems, Inc. specializes in the design, development, and manufacture of bio-absorbable implants used in soft tissue fixation during facial cosmetic surgery. The company offers a range of products, including the ENDOTINE Forehead 3.0 and ENDOTINE Triple 3.0, which are designed for brow fixation, along with ENDOTINE Midface ST 4.5 for midface suspension. Other offerings include the ENDOTINE Ribbon and various surgical tools such as manual surgical drills and incisionless dissectors for precise application. Coapt's implants are utilized in procedures like forehead lifts, brow lifts, and midface and neck suspensions, catering to the needs of plastic surgeons in enhancing patient outcomes.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide decisions on chemotherapy, hormonal therapy, or alternative treatments, thereby improving patient outcomes and reducing healthcare costs.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide decisions on chemotherapy, hormonal therapy, or alternative treatments, thereby improving patient outcomes and reducing healthcare costs.

Nitec is a specialty pharmaceutical company focused on the commercialization and development of medicines to treat chronic inflammation and pain-related diseases. It seeks to address areas of high unmet medical need within these markets by developing proprietary products based on well-characterized pharmaceuticals and disease targets. The Company is a spin-out of Merck KGaA and is headquartered in the Basel region of Switzerland. Since its formation in 2004, Nitec has developed and commercialized its lead product, Lodotra™. Nitecâ€:tm:s most advanced product candidate is Lodotra™, a circadian cytokine modulator, which successfully completed a European phase 3 trial in rheumatoid arthritis (RA) in 2006. In January 2009, Lodotra™ was recommended for European regulatory approval for the treatment of rheumatoid arthritis (“RA“), particularly the associated and debilitating morning stiffness, following the successful completion of a phase III trial (CAPRA-1) in 2006. Germany was the Reference Member State and Lodotra™ is now also expected approvable by the regulatory agencies of 14 other countries under the Decentralized Procedure. In March Nitec announced a European partnership for Lodotraâ€:tm:s commercialization with MundiPharma. Merck KGaA, which holds the distribution rights to Lodotra™ in Germany and Austria, have recently launched the product in Germany. Nitec is conducting a second pivotal phase 3 trial in preparation for the filing of an NDA with the FDA seeking US approval of Lodotra™ for the treatment of the signs and symptoms of RA including morning stiffness. Lodotra™ is also being developed for the treatment of severe asthma and polymyalgia rheumatica (PMR). Nitecâ€:tm:s second product candidate is TruNoc™ (tarenflurbil), which is being developed as a treatment of neuropathic pain and other chronic inflammation and pain-related diseases. Nitec is conducting pharmacokinetic studies in preparation for phase 2 trials in neuropathic pain.

Coapt Systems, Inc. specializes in the design, development, and manufacture of bio-absorbable implants used in soft tissue fixation during facial cosmetic surgery. The company offers a range of products, including the ENDOTINE Forehead 3.0 and ENDOTINE Triple 3.0, which are designed for brow fixation, along with ENDOTINE Midface ST 4.5 for midface suspension. Other offerings include the ENDOTINE Ribbon and various surgical tools such as manual surgical drills and incisionless dissectors for precise application. Coapt's implants are utilized in procedures like forehead lifts, brow lifts, and midface and neck suspensions, catering to the needs of plastic surgeons in enhancing patient outcomes.

Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising, Bayern.

IMI Intelligent Medical Implants develops and markets intelligent retinal implant systems for degenerative retinal disorders. The company offers The Intelligent Retinal Implant System, an adaptive visual prosthesis that bridges and replaces the defective information processing function of the real retina in patients with retinal degeneration. IMI Intelligent Medical Implants was founded in 2002 and is based in Zug, Switzerland.

NeurogesX, Inc. is a specialty pharmaceutical company based in San Mateo, California, established in 1998. Originally named Advanced Analgesics, Inc., the company focuses on developing and commercializing innovative non-opioid therapies for pain management, specifically targeting chronic peripheral neuropathic pain conditions such as postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Its lead product, Qutenza, is an 8% capsaicin dermal patch designed to alleviate pain associated with these conditions. Additionally, NeurogesX is working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, as well as an opioid analgesic for managing pain due to other chronic conditions, including cancer pain.

Nitec is a specialty pharmaceutical company focused on the commercialization and development of medicines to treat chronic inflammation and pain-related diseases. It seeks to address areas of high unmet medical need within these markets by developing proprietary products based on well-characterized pharmaceuticals and disease targets. The Company is a spin-out of Merck KGaA and is headquartered in the Basel region of Switzerland. Since its formation in 2004, Nitec has developed and commercialized its lead product, Lodotra™. Nitecâ€:tm:s most advanced product candidate is Lodotra™, a circadian cytokine modulator, which successfully completed a European phase 3 trial in rheumatoid arthritis (RA) in 2006. In January 2009, Lodotra™ was recommended for European regulatory approval for the treatment of rheumatoid arthritis (“RA“), particularly the associated and debilitating morning stiffness, following the successful completion of a phase III trial (CAPRA-1) in 2006. Germany was the Reference Member State and Lodotra™ is now also expected approvable by the regulatory agencies of 14 other countries under the Decentralized Procedure. In March Nitec announced a European partnership for Lodotraâ€:tm:s commercialization with MundiPharma. Merck KGaA, which holds the distribution rights to Lodotra™ in Germany and Austria, have recently launched the product in Germany. Nitec is conducting a second pivotal phase 3 trial in preparation for the filing of an NDA with the FDA seeking US approval of Lodotra™ for the treatment of the signs and symptoms of RA including morning stiffness. Lodotra™ is also being developed for the treatment of severe asthma and polymyalgia rheumatica (PMR). Nitecâ€:tm:s second product candidate is TruNoc™ (tarenflurbil), which is being developed as a treatment of neuropathic pain and other chronic inflammation and pain-related diseases. Nitec is conducting pharmacokinetic studies in preparation for phase 2 trials in neuropathic pain.

Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury. Spinal Cord Therapeutics focuses on the treatment of traumatic injury to the central nervous system.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide decisions on chemotherapy, hormonal therapy, or alternative treatments, thereby improving patient outcomes and reducing healthcare costs.

CombinatoRx is a biotech company that develops medicines from synergistic combinations of approved drugs. The company has pushed into Phase 2 clinical trials a portfolio of drug candidates aimed at cancer and multiple immuno-inflammatory diseases. CombinatoRx Service Business was acquired by Horizon Discovery Group.

CareX SA is a biopharmaceutical company that develops novel treatments for metabolic and immune system disorders which includes diabetes and obesity. The company focuses on metabolic syndrome, a cluster of inter-related disorders of the body’s metabolism, including high blood pressure, high insulin levels, excess body weight, and abnormal cholesterol levels, that exposes individuals to the development of type 2 diabetes, heart diseases, and strokes. CareX SA is a France-based company that was founded in 2001 and the company was acquired by 7TM Pharma on May 24, 2006.

Zalicus Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the development of drug candidates aimed at treating pain and inflammation. The company specializes in ion-channel modulation, using its expertise to discover therapeutics that may effectively block ion channels in neuronal cells responsible for pain signal transmission. Zalicus has invested significantly in its drug discovery technology, as well as the research and development of its product candidates, which includes conducting preclinical and clinical trials. The company has also sought intellectual property protection for its innovative technologies. Its notable achievement includes the approval of Exalgo, an extended-release formulation of hydromorphone for managing moderate to severe pain in opioid-tolerant patients, granted by the United States Food and Drug Administration in 2010. Additionally, Zalicus merged with Neuromed Pharmaceuticals in 2009, further expanding its capabilities in pain management therapies.

NeurogesX, Inc. is a specialty pharmaceutical company based in San Mateo, California, established in 1998. Originally named Advanced Analgesics, Inc., the company focuses on developing and commercializing innovative non-opioid therapies for pain management, specifically targeting chronic peripheral neuropathic pain conditions such as postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Its lead product, Qutenza, is an 8% capsaicin dermal patch designed to alleviate pain associated with these conditions. Additionally, NeurogesX is working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, as well as an opioid analgesic for managing pain due to other chronic conditions, including cancer pain.

FRIZ Biochem GmbH, founded in Oct. 2004, is a privately-held biotech company located in Neuried near Munich. The company initially focused on the development of advanced electronic biochips and gradually integrated the complete workflow of molecular diagnostics into its development efforts. FRIZ Biochem offers novel, highly innovative and broadly applicable molecular diagnostics solutions (instruments, analytical techniques, chemistries, sample preparation etc.) with special emphasis on Point-of-Care applications. FRIZ Biochem addresses the challenge of providing a combination of simplification and improved information in a time-frame where the result affects medical intervention.

Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.

Founded in 1997 and headquartered in Wellesley, Massachusetts, Coley Pharmaceutical Group is a biopharmaceutical company focused on developing therapeutics that harness the human immune system to combat cancers, asthma and allergy, autoimmune disorders, and enhance vaccine effectiveness. The company's platform specializes in vaccine adjuvant technology and immunomodulatory drug candidates.

Intercell AG, a biotechnology company, engages in the design and development of vaccines for the prevention and treatment of infectious diseases. It discovers and develops antigens and adjuvants, which are derived from its proprietary technology platforms. The company was founded in 1998 and is headquartered in Vienna, Austria.

BrainGate is a path to a better way of life for severely motor-impaired individuals. Through years of advanced research, BrainGate enables these people with the ability to communicate, interact and function through thought. (view video) BrainGate's mission is to further the advancement of this life-changing technology to promote wider adoption to help impaired individuals communicate and interact with society. For instance, the Cyberkenetics BrainGate Neural Interface is currently the subject of a pilot clinical trial being conducted under an Investigational Device Exemption (IDE) from the FDA. The system is designed to restore functionality for a limited, immobile group of severely motor-impaired individuals. It is expected that people using the BrainGate System will employ a personal computer as the gateway to a range of self-directed activities. These activities may extend beyond typical computer functions (e.g., communication) to include the control of objects in the environment such as a telephone, a television and lights.

Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising, Bayern.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.

Kuros Biosciences is a Swiss biopharmaceutical company founded in 2000 as a spin‑off of ETH Zürich. It develops tissue‑repair and bone‑regeneration products built on proprietary technology platforms derived from research at ETH Zürich, the University of Zürich and CalTech. The company acquired Xpand Biotechnology in 2017 to expand its MagnetOs family of bone graft substitutes, which are approved in the EU for orthopedic, spinal and dental applications and in the United States for posterolateral spinal fusion. A putty formulation is pending regulatory submission. Neuroseal, a novel dural‑sealing biomaterial, is under CE review. Kuros also pursues a pipeline of clinical‑stage products, including KUR‑111 and KUR‑113 for fracture repair and a fibrin‑PTH combination that promotes bone formation. The company collaborates with Checkmate Pharmaceuticals on the oncology candidate CYT003 and maintains a legacy portfolio of medical‑device and pharmaceutical assets.

Agromed S.A. engages in the manufacture, marketing, and sale of dairy products. It offers UHT milks, yogurts, desserts, cheeses, and butter. The company sells its products to supermarkets, wholesalers, and small grocery stores in Tunisia. Agromed S.A. is based in Sfax, Tunisia.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.